Catherine O’Connor

Presented at #ELCC26: In a phase 1 trial of setidegrasib, a KRAS G12D degrader, 42% of patients had adverse events of grade 3 or higher; 36% of patients with NSCLC and 24% of those with pancreatic cancer had a response. Full trial results: nejm.org/doi/full/10.10… @myESMO

1/n Now published in @NatureMedicine : The phase 2 #POLAR trial of pembrolizumab + olaparib maintenance in metastatic pancreatic cancer. @CpcrMsk @MSKCancerCenter @MSK_DeptOfMed @PICIatMSK rdcu.be/e9WmJ

Early-onset gastrointestinal cancers: comprehensive review and future directions ➡️doi.org/10.1093/bjs/zn… ⏰Early-onset GI cancers represent clinically distinct disease entities that are associated with unique challenges in screening, management, and survivorship 🚨A better understanding of underlying aetiologies, optimized screening strategies, and improved survivorship support are necessary 🧑‍🤝‍🧑Meeting the needs of this growing patient population will require a multidisciplinary, equity- based approach in both clinical care and research Work by @SaraKCharMD, @CatherineaOC and @KimmieNgMD #SoMe4Surgery #MedTwitter #SurgEd #Surgery @RCPSGTrainees @aecirujanos @SEIQuirurgica @iss_sic #MedicalTechniques @des_winter @evanscolorectal @robhinchliffe1 @bplwijn @MalinASund @nfmkok @TejedorPat @paulo_sutt @PVaughanShaw @JJEarnshaw @juliomayol @ksoreide @BJSAcademy @young_bjs @BJSOpen #colorectalsurgery #StepUp4CRC @FightCRC @ACPGBI #ERAS @dice_europe #Crohn #proctology @Dukes_Club @ACPGBI_EduTrain @AECP_FAECP @PelvExGroup @escp_tweets @YouESCP #TeachMeColoproctology #Some4COLoprocto @PSOGI_EC #GICancer #EarlyOnset #OncologyCare @CatherineaOC

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: nej.md/4mh5RPL @ASCO

Sara K. Char, MD @SaraKCharMD @DanaFarber will present the findings of a dietary and lifestyle substudy based on data from CALGB/SWOG 80702 (Alliance) at #ASCO25. Read more about Alliance at ASCO: bit.ly/AllianceAtASCO #NCI @ALLIANCE_org #NCI #NCTN #NCORP

How can we bridge the gap between aspiration and reality in cancer #PalliativeCare? A new commentary examines the latest @ASCO guideline update, its practical challenges, & strategies for systemic change. Read more: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @FionnualaCrowle @OncoAlert

Excited to be in Houston for #SITC2024 with my mentor @CentralParkWMD and to present our small cohort study looking at chemoimmunotherapy for treatment of metastatic Pancreatic Neuroendocrine Carcinoma!

Adjuvant mFOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC): Clinical Insights and Genomic Features from a Large Contemporary Cohort academic.oup.com/jnci/article-a… Congrats to @ferguskeane2 @CatherineaOC @FiyinfoluB @DrewMoss for very thoughtful compilation synthesis of data!

An important single institution study led by @EileenMOReilly from @MSKCancerCenter in @JNCI_Now Adjuvant Modified FOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC): Clinical Insights and Genomic Features from a Large Contemporary Cohort academic.oup.com/jnci/advance-a… With all the caveats of a retrospective single center study, and limitations of small genetic subsets (like only a few HRD patients that may explain the absence of correlation with improved response), this is still an important demonstration for WHY earlier detection, successful surgery and timely administration of adjuvant therapy (even with reduced doses) is SO pivotal to longer survival. OS stratified by age below.

Weekend spent well 🥰 visiting Boston~ so lovely 💜 🏃🏻 a bit for the #TCSNYCMarathon 2024 @nyrr with @IRDocDay Beautiful cool weather today~ Enjoyed amazing regatta rowing 🚣‍♀️ race in Charles River 🌊and visited my favorite mentee @CatherineaOC Missing my research team in NYC!!